Key Points
- Medifast director Parsa Kiai bought 43,150 shares at an average price of $11.60, investing $500,540 and increasing direct ownership by 6.98% to 661,306 shares. Kiai also purchased $342,069 worth of shares the previous day.
- Medifast reported quarterly revenue of $76.38 million and an adjusted loss of $0.28 per share, beating estimates for $72.70 million in revenue and a $0.65 per-share loss, though net margin and return on equity remained negative.
- Analyst sentiment remains cautious, with a consensus “Reduce” rating and a $12.00 price target. The stock recently opened at $12.00, with a 52-week range of $9.22 to $14.67.
Medifast Inc (NYSE:MED - Get Free Report) Director Parsa Kiai bought 29,337 shares of the firm's stock in a transaction on Wednesday, August 19th. The shares were bought at an average cost of $11.66 per share, with a total value of $342,069.42. Following the purchase, the director directly owned 619,331 shares in the company, valued at approximately $7,221,399.46. This trade represents a 4.97% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Parsa Kiai also recently made the following trade(s):
- On Thursday, August 20th, Parsa Kiai purchased 43,150 shares of Medifast stock. The stock was bought at an average cost of $11.60 per share, for a total transaction of $500,540.00.
Medifast Trading Up 3.3%
Shares of NYSE:MED opened at $12.00 on Friday. The firm has a market cap of $134.17 million, a price-to-earnings ratio of -5.15 and a beta of 0.65. Medifast Inc has a 1 year low of $9.22 and a 1 year high of $14.67. The business has a fifty day simple moving average of $10.92 and a 200 day simple moving average of $11.06.
Medifast (NYSE:MED - Get Free Report) last issued its earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.37. The company had revenue of $76.38 million for the quarter, compared to analyst estimates of $72.70 million. Medifast had a negative return on equity of 6.69% and a negative net margin of 8.08%.Medifast has set its FY 2026 guidance at -1.750--0.250 EPS and its Q3 2026 guidance at -0.650--0.150 EPS. On average, sell-side analysts forecast that Medifast Inc will post -1 EPS for the current year.
Wall Street Analyst Weigh In
MED has been the topic of several analyst reports. Weiss Ratings upgraded shares of Medifast from a "sell (e+)" rating to a "sell (d)" rating in a research note on Monday. Zacks Research cut shares of Medifast from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 11th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Medifast presently has an average rating of "Reduce" and a consensus price target of $12.00.
View Our Latest Analysis on Medifast
Hedge Funds Weigh In On Medifast
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State of Wyoming raised its position in shares of Medifast by 19.8% in the first quarter. State of Wyoming now owns 6,646 shares of the specialty retailer's stock valued at $68,000 after purchasing an additional 1,097 shares during the period. BNP Paribas Financial Markets raised its holdings in Medifast by 103.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer's stock worth $32,000 after acquiring an additional 1,187 shares during the period. Man Group plc raised its holdings in Medifast by 0.6% in the 2nd quarter. Man Group plc now owns 198,156 shares of the specialty retailer's stock worth $2,784,000 after acquiring an additional 1,200 shares during the period. JPMorgan Chase & Co. lifted its position in Medifast by 2.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 53,341 shares of the specialty retailer's stock worth $749,000 after acquiring an additional 1,316 shares during the last quarter. Finally, Barclays PLC lifted its position in Medifast by 10.6% during the 4th quarter. Barclays PLC now owns 16,769 shares of the specialty retailer's stock worth $179,000 after acquiring an additional 1,608 shares during the last quarter. Institutional investors and hedge funds own 95.51% of the company's stock.
Medifast Company Profile
(
Get Free Report)
Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client's weight‐loss journey.
Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
